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Abstract
Background
Systemic sclerosis (SSc) is characterized by excessive fibrosis throughout the body. This
leads to the release of extracellular matrix (ECM) fragments into circulation, where they may
be quantified as biomarkers. The objectives were to investigate levels of ECM turnover bio-
markers and the diagnostic power of these.
Methods
Diffuse SSc patients (n = 40) fulfilling the ACR/EULAR 2013 classification criteria and
asymptomatic controls were included. Patients were divided into early (<2 years of symp-
toms; n = 20) and late (>10 years of symptoms; n = 20) diffuse SSc. Biomarkers of type I
(C1M), III (C3A, C3M), IV (C4M), V (C5M) and VI (C6M) collagen degradation and type I
(PRO-C1), II (PRO-C2), III (PRO-C3), IV (PRO-C4), V (PRO-C5) and VI (PRO-C6) collagen
formation were measured in serum.
Repeated measures ANOVA was used to test for differences in biomarker levels and the
area under the receiver operating characteristic curve (AUC) was used to investigate the
ability of the biomarkers to separate groups.
Results
In early diffuse SSc, formation biomarkers of type III, IV, V and VI collagen were significantly
increased compared to asymptomatic controls (p<0.0001). Moreover, in early diffuse SSc
formation biomarkers of type III, V and VI collagen were significantly increased compared to
late diffuse SSc (p = 0.0006, 0.003 and 0.004, respectively). Type I (p<0.0001), III (C3M: p =
0.001, and C3A: p = 0.02), IV (p<0.0001) and VI (p<0.0001) collagen degradation biomark-
ers significantly increased in early diffuse SSc compared to controls. C4M, C6M, PRO-C4,
PRO-C5 and PRO-C6 had an AUC of >0.85 when assessing asymptomatic controls vs. dif-
fuse SSc. Biomarkers of type VI collagen (PRO-C6 and C6M) turnover had the best separa-
tion with an AUC’s of >0.90.
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Conclusion
Formation biomarkers of ECM turnover were shown to be significantly different between
asymptomatic controls and diffuse SSc. This pilot study suggest that serological biomarkers
of the ECM turnover is potentially applicable in SSc.
Introduction
Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease of unknown etiology. One
of its main characteristics is fibrosis of the skin and internal organs. The distribution of skin
involvement is used to stratify patients into limited and diffuse cutaneous SSc, where diffuse
cutaneous SSc is characterized by skin involvement of the trunk, face, proximal, and distal
extremities[1]. Diffuse SSc is a more aggressive disease compared to limited cutaneous SSc
with increased organ involvement and mortality[2–4]. SSc is thought to progress in two
phases; an early, very active period followed by a slower progressing period.
Mammalian skin consists of several distinct layers. The outer most layer is the epidermis
and the basal layer of the epidermis is attached to a basement membrane that overlays the con-
nective tissue layer, known as the dermis. The predominant extracellular matrix (ECM) com-
ponent of the skin is collagen. The two major collagens found are type I and III collagen,
which are mainly found in the dermis[5]. Type IV, V and VI collagen are found at minor con-
centrations in the skin. Type IV collagen is located in the basement membrane in the junction
of the epidermis and dermis[6]. Type V collagen is co-located with type I and III collagen in
the dermis, where it plays an important role in regulating the fibrils[7]. Type VI collagen is
likewise distributed throughout the dermis[8]. Dermal accumulation of type I and III collagen
and up-regulation of other ECM proteins, including fibronectin, osteopontin, and SPARC, are
observed during dermal fibrosis[9].
ECM remodeling releases a vast number of protein fragments into circulation. These frag-
ments include both pro-peptides and protease generated degradation fragments of the ECM
proteins. They describe the status of the ECM from where they originate and can be used to
assess ECM turnover, i.e. natural tissue remodeling and diseases as fibrosis. The shifted bal-
ance in tissue remodeling during different diseases can be assessed by these protein fragments.
Several collagen fragments have been identified as possible diagnostic, prognostic, and pre-
dictive biomarkers in various arthritic and fibrotic diseases[10–17]. The pro-peptide of type III
collagen (PRO-C3) has been shown to be diagnostic of liver fibrosis[10], while the degradation
of type III collagen (C3M) has diagnostic capacities for idiopathic pulmonary fibrosis[11],
rheumatoid arthritis (RA)[12] and ulcerative colitis[13]. The pro-peptide of type IV collagen
(PRO-C4) has shown to be diagnostic of liver fibrosis[14], while the matrix metalloproteinase
(MMP) degraded type IV collagen (C4M) has shown to be diagnostic of idiopathic pulmonary
fibrosis (IPF)[15]. The pro-peptide of type V collagen (C5M) has shown diagnostic relevance
with liver fibrosis[16] and to be a possible diagnostic tool for ankylosing spondylitis[17]. A
type VI collagen degradation biomarker (C6M) have shown to have prognostic capacity in IPF
[11]. MMP-degraded type I collagen (C1M) has shown to be predictive of radiographic pro-
gression in RA[18].
SSc is a multi-organ disease, known to affect joints, the gastrointestinal system, lungs, and
liver. Biomarkers of these organs may be useful in SSc as diagnostic or predictive biomarkers.
Such biomarkers have been briefly explored in SSc, where differences in biomarker levels
between healthy controls and SSc has been observed for different collagen formation
Collagen turnover biomarkers as diagnostic toll in systemic sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0207324 December 3, 2018 2 / 12
Competing interests: NF and JC are employees
and shareholders of Biogen. AB, MK, and AS are
employees at Nordic Bioscience and AB and MK
own stock in Nordic Bioscience. PJ and AS have no
financial interests in Nordic Bioscience or Biogen.
This does not alter the authors’ adherence to PLOS
ONE policies on sharing data and materials. All
authors critically reviewed the manuscript and
approved the final version for submission.
biomarkers[19–21]. PINP and PIIINP have been examined in clinical studies of SSc with vary-
ing results. Studies have shown that PINP and PIIINP do not consistently correlate with
changes in modified Rodnan skin score (mRSS)[20, 22, 23].
There is an unmet need of objective serological biomarkers that can stratify patients. A bet-
ter understanding of disease progression will aid in the development of better treatments.
Investigations so far have only scratched the surface, but indications that serological biomark-
ers may be of value have been presented.
The objective of this study was to investigate the level of collagen protein fingerprint bio-
markers in diffuse SSc (early and late) compared to asymptomatic controls and determine the
diagnostic value of these biomarkers. This was done by quantifying the ECM biomarkers in a
cross-sectional study comprising early and late diffuse SSc patient and asymptomatic controls.
Methods
Patients
Forty SSc patients were identified from the University of Pittsburgh Medical Center and Uni-
versity of Pittsburgh Scleroderma center observational cohort study, which consists of pro-
spectively collected data and serum samples. Serum samples were collected from study
subjects and stored at -80˚C until measured. All SSc patients met the 2013 combined ACR/
EULAR criteria[24], were > 18 years at the time of first visit, and had diffuse disease, defined
as skin thickening proximal to the elbows and knees. Of the diffuse SSc patients, half (n = 20)
of the patients had early stage disease defined as< 2 years since the first SSc symptom. Twenty
patients were late stage SSc, with 10 or more years of symptoms, and no change in mRSS for at
least six months prior to the serum sample. If diffuse SSc patients had interstitial lung disease,
this was stable by forced vital capacity (FVC) for at least one year prior to the studied serum
sample. Asymptomatic control sera were also taken from the Pittsburgh serum bank and did
not have a personal or first-degree relative medical history of autoimmune disease.
All participants gave written, informed consent before inclusion in the study. The study
was approved by the University of Pittsburgh institutional review board (approval number
IRB0409097) and carried out in accordance with the principles of the declaration of Helsinki.
Serological protein fingerprint biomarkers for ECM turnover
ECM degradation was assessed by type I collagen (C1M)[25], type III collagen (C3A;(unpub-
lished) and C3M)[26], type IV collagen (C4M)[15], type V collagen (C5M)[17], and type IV
collagen (C6M). ECM formation was assessed by the N-terminal type I collagen pro-peptide
(PRO-C1)[27], the N-terminal pro-peptide of type II collagen (PRO-C2)[28], N-terminal pro-
peptide of type III collagen (PRO-C3)[10], type IV collagen pro-peptide (PRO-C4)[29], C-ter-
minal pro-peptide of type V collagen (PRO-C5)[16] and C-terminal pro-peptide of type VI
collagen (PRO-C6)[30]. During assay development, cross-reactivity of the antibodies was
examined. This was done by blasting the sequence of the antigen to ensure it is unique and the
antibodies reaction to elongated and truncated peptides and no reactivity was found[30].
The described degradation and formation protein fingerprint biomarkers were assessed by
validated competitive ELISAs. In summary, plates with streptavidin bound to the bottom, was
coated with biotinylated peptide, corresponding to the specific epitopes to be assessed in the
individual assay. This was incubated for 30 min at 20˚C with agitation, followed by washing in
washing buffer (20mM TRIS, 50mM NaCl, pH 7.2) five times. Twenty uL sample was added
and 100uL antibody specific for the different epitopes in the individual assay was added. This
was incubated either for 1 hour at 20˚C, or 3 hours or 20 hours at 4˚C. The plate was washed
five times in washing buffer, before 100uL TMB was added to develop the ELISA. The enzyme
Collagen turnover biomarkers as diagnostic toll in systemic sclerosis
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reaction was stopped after 15 min by 0.1M H2SO4, before reading the plate at 450 nm with
650nm as reference. For PRO-C2 there was an additional step before TMB was added as 100
uL secondary antibody was added for 1 hour at 20˚C. An overview of the assays used can be
found in Table 1.
Statistics
Summary statistics were used to generate Table 2. Repeated measures ANOVA was used to
test for differences in biomarker level between groups; asymptomatic controls, early diffuse,
and late diffuse. Although biomarker data were not normally distributed, the assumptions of
repeated measures ANOVA were fulfilled as the data were continuous and independent, there
were no significant outliers, the distribution of the differences in the variables was approxi-
mately equal and the data showed sphericity. The area under the receiver operating
Table 1. Technical performance of the protein fingerprint biomarkers.
Measuring range (ng/mL) IC50 (ng/mL) Inter-assay (%) Intra-assay (%)
C1M 10–200 21–33 6.7–14 2.8–8.8
C3A 1.5–200 8–11 5.5–20 3–12
C3M 1–22 3–6 6.6–15.1 2–4.1
C4M 2.2–72 5–7 5–15 4–10
C5M 1–14 4.5–5.5 4.6–14 1–4.1
C6M 3–133.5 25–35 4–18 2–8
PRO-C1 7–258 45–60 3–13 1–8
PRO-C2 1.9–38.2 8.25 10 7
PRO-C3 1.3–58 5.5–8.5 8–12 1.8–9.3
PRO-C4 6–348.5 37.4–67.3 5.2–17.6 2.8–5.8
PRO-C5 32.5–1189 80–112 5–15 2–9
PRO-C6 0.4–67 3.5–5 3.4–12.4 1.1–5.3
https://doi.org/10.1371/journal.pone.0207324.t001
Table 2. Clinical and demographic features of systemic sclerosis subjects and asymptomatic controls.
Characteristics Early diffuse SSc
(n = 20)
Late diffuse SSc
(n = 20)
Asymptomatic controls
(n = 20)
p-value
Demographics
Mean age (±SD) in years at the time sample 54.0 ± 11.9 57.3 ± 14.7 45.5 ± 14.8 0.03
Gender (% female) 65% 85% 75% 0.34
Disease and Exam Characteristics
Median (IQR) disease duration in years (from first SSc-attributable
symptom)
0.8 (0.5, 1.2) 12.5 (10.6, 16.5) <0.001
Median modified Rodnan skin score (IQR) 26.0 (10.5, 32.0) 7.0 (1.5, 9.5) <0.001
Internal organ system involvement
Raynaud phenomenon 90% 100% 0.49
Pulmonary 55% 90% 0.01
Renal crisis 5% 0% 0.31
Cardiac 0% 5% 0.31
Gastrointestinal 45% 75% 0.05
Pulmonary hypertension 0% 5% 0.31
SD: Standard deviation, IQR: interquartile range. For demographics, p-values were calculated by One-way ANOVA and for Disease and exam characteristics as well as
internal organ involvement, p-values were calculated by t-test.
https://doi.org/10.1371/journal.pone.0207324.t002
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characteristic curve (AUC) was used to investigate the ability of the biomarkers to identify
cases from controls[31]; SSc groups from controls and early from late SSc groups.
All data are shown as mean + standard error of mean (SEM), if not otherwise stated. All
data analysis and graphical illustration was performed using GraphPad Prism version 6.00 for
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com or SAS 9.3 (SAS
Institute, Cary, NC).
Results
Baseline demographics
The mean age of patients in the three groups were significantly different, with a younger
asymptomatic control group (mean age: 45.5 years, p = 0.03). Early and late diffuse patients
significantly differed on disease duration (p<0.001) and mRSS (p<0.001). Furthermore, a sig-
nificant difference in pulmonary (p = 0.01) and gastrointestinal involvement was observed
(p = 0.05; Table 2).
Biomarker levels in the study population
One of the hallmarks of SSc is excessive ECM deposition in both the skin and internal organs.
ECM turnover biomarkers can serologically assess tissue turnover. In both early and late dif-
fuse SSc patients formation and degradation biomarkers were generally increased compared to
asymptomatic controls (Figs 1 and 2). PRO-C3, PRO-C4, PRO-C5 and PRO-C6 levels (all
p<0.0001) were found to be significantly increased in early diffuse SSc compared to asymp-
tomatic controls (Fig 1). In early diffuse SSc a significant higher level of PRO-C3 (p<0.0001)
and PRO-C6 (p<0.0001) was found compared to late diffuse SSc. Furthermore, PRO-C4
(p = 0.006), PRO-C5 (p = 0.004) and PRO-C6 (p = 0.01) was found to be significantly
increased in late diffuse SSc compared to healthy controls. Contrary, PRO-C1 was significantly
lower in early (p = 0.02) and late (p = 0.002) diffuse SSc compared to asymptomatic controls. I
an earlier study[19], PRO-C3, PRO-C4, and PRO-C5 showed a significantly difference in the
fold change of serum biomarker levels between SSc patients and asymptomatic controls, simi-
lar to this study.
In early diffuse SSc, C1M, C4M and C6M (p<0.0001), C3A (p = 0.015) and C3M
(p = 0.001) were found to be significantly increased compared to asymptomatic controls (Fig
2). Furthermore, in late diffuse SSc patients a significant increase was found compared to
asymptomatic controls in C3A (p = 0.0055), C3M (p = 0.025), C4M (p = 0.0057), and C6M
(p = 0.0005). C1M (p = 0.02), C4M (p = 0.22), and C6M (p = 0.05) was found to be signifi-
cantly increased in early diffuse SSc compared to late diffuse SSc. These data confirm the
observed significant difference in C4M and C6M levels between SSc and asymptomatic con-
trols as observed previously[19].
Diagnostic evaluation
Due to the highly significant difference between asymptomatic controls and SSc in many of
the biomarkers, the diagnostic capacity of the biomarkers was assessed (Table 3). The individ-
ual biomarkers of C4M, C6M, PRO-C4, PRO-C5, and PRO-C6 each demonstrated an AUC
>0.85 to distinguish SSc vs asymptomatic controls. Similarly, C1M, C4M, C6M, PRO-C3,
PRO-C4, PRO-C5, and PRO-C6 were calculated to have an AUC of>0.85 to classify asymp-
tomatic controls vs. early diffuse SSc and C3A, C6M, and PRO-C6 had an AUC of>0.85 to
distinguish late diffuse SSc vs. asymptomatic controls. PRO-C3, and PRO-C6 showed an AUC
of>0.85, when comparing early diffuse vs. late diffuse. PRO-C6 had the highest diagnostic
Collagen turnover biomarkers as diagnostic toll in systemic sclerosis
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Fig 1. Collagen formation biomarker levels in asymptomatic controls and SSc groups. Type I collagen formation. B: Type II collagen
formation. C: Type III collagen formation. D: Type IV collagen formation. E: Type V collagen formation. F: Type VI collagen formation. Repeated
measures ANOVA (Kruskal-Wallis with Dunn’s multiple comparisons test) was used for statistical analysis, between asymptomatic controls, late
and early diffuse SSc. Asymptomatic controls: n = 20, early SSc: n = 20 and late SSc: n = 20.
https://doi.org/10.1371/journal.pone.0207324.g001
Collagen turnover biomarkers as diagnostic toll in systemic sclerosis
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Fig 2. Collagen degradation biomarker levels in asymptomatic controls and SSc groups. A: Type I collagen degradation. B: Type III
collagen degraded by aggrecanses. C: Type III collagen degraded by MMPs. D: Type IV collagen degradation. E: Type V collagen
degradation. F: Type VI collagen degradation. Repeated measures ANOVA (Kruskal-Wallis with Dunn’s multiple comparisons test) was
Collagen turnover biomarkers as diagnostic toll in systemic sclerosis
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power with an AUC of 0.99 (specificity/sensitivity: 95/95) and C6M had an AUC of 0.94 (90/
90) for asymptomatic controls vs. early diffuse SSc. When assessing the separation of asymp-
tomatic controls vs. late diffuse SSc, an AUC of 0.87 (80/75) were observed for PRO-C6 and an
AUC of 0.91 (95/75) for C6M.
used for statistical analysis, between asymptomatic controls, late and early diffuse SSc. Asymptomatic controls: n = 20, early SSc: n = 20
and late SSc: n = 20.
https://doi.org/10.1371/journal.pone.0207324.g002
Table 3. Area under the curve, with corresponding sensitivity and specificity of the biomarkers as diagnostic tools.
Ctrl vs. Early SSc Ctrl vs. late SSc Early SSc vs. late SSc
C1M AUC 0.87��� 0.67 0.77
Sensitivity/specificity % 85/75 80/45 70/65
Likelihood ratio 3.4 2.3 2.2
C3A AUC 0.83 0.86� 0.54
Sensitivity/specificity % 89/80 89/84 45/68
Likelihood ratio 4.4 5.6 1.4
C3M AUC 0.82� 0.76 0.59
Sensitivity/specificity % 75/75 75/70 65/55
Likelihood ratio 3.0 2.5 1.4
C4M AUC 0.93��� 0.84�� 0.71
Sensitivity/specificity % 74/95 58/95 60/80
Likelihood ratio 14.74 11.6 3
C5M AUC 0.54 0.66 0.60
Sensitivity/specificity % 50/69 50/74 88/47
Likelihood ratio 1.6 1.9 1.7
AUC 0.94��� 0.91��� 0.68
C6M Sensitivity/specificity % 90/90 75/95 65/70
Likelihood ratio 9 15.0 2.2
PRO-C1 AUC 0.77��� 0.80 0.57���
Sensitivity/specificity % 70/75 70/70 65/55
Likelihood ratio 2.8 2.3 1.4
PRO-C3 AUC 0.91��� 0.61 0.86���
Sensitivity/specificity % 85/90 75/55 80/85
Likelihood ratio 8.5 1.7 5.3
PRO-C4 AUC 0.91��� 0.81�� 0.66
Sensitivity/specificity % 80/90 75/85 50/80
Likelihood ratio 8.0 5.0 2.5
PRO-C5 AUC 0.91��� 79/85 0.68
Sensitivity/specificity % 95/85 79/85 55/75
Likelihood ratio 6.3 5.3 2.2
PRO-C6 AUC 0.99��� 0.87��� 0.88���
Sensitivity/specificity % 95/95 79/85 70/90
Likelihood ratio 19.0 3.8 7.0
Bonferroni correction was used to find the new critical p-value < 0.0045.
�: <0.0045
��: <0.0005
���: <0.0001.
Ctrl: asymptomatic controls
https://doi.org/10.1371/journal.pone.0207324.t003
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Furthermore, an AUC of 0.88 (90/70) for early diffuse vs. late diffuse SSc for PRO-C6 was
found. C4M, PRO-C3, PRO-C4, and PRO-C5 were all found to have AUC’s of>0.90 when
classifying asymptomatic controls vs. early diffuse SSc.
The biomarker examined in this study needs to be further validated in other cohorts. As
this was a small, exploratory cohort there are limitations to this study. The cohort consisted of
20 early and 20 late diffuse SSc patients. More patients are warranted to determine if these bio-
markers performs as well in a larger cohort. Furthermore, patients were only examined at one
time point and it is therefore not possible to examine the biomarkers over time and in regards
to progression. Lastly, treatments and organ involvement was not taken into account. These
might affect the biomarkers, as the collagens are present in other tissues as well.
Discussion
There is a lack of objective biomarkers that stratify patients, predict organ involvement, and
identify progressors. Furthermore, SSc is still a disease of unknown etiology and a greater
understanding of the disease progression is still need for the development of better treatments.
In this study, we found that ECM biomarkers levels were increased in diffuse SSc, especially in
early diffuse SSc. In addition, we found that several of these biomarkers have potential to be
diagnostic tools in SSc and distinguishing between early and/or late diffuse SSc compared to
asymptomatic controls. PRO-C6 was the best biomarker to differentiate between early and late
diffuse SSc with an AUC of 0.88 (sensitivity/specificity of 70%/90%). Turnover of type VI col-
lagen (PRO-C6 and C6M, respectively) were the best biomarkers to differentiate between
asymptomatic and early diffuse SSc with AUCs of 0.99 (95%/95%) and 0.91 (90%/90%),
respectively.
A biomarker of the N-terminal pro-peptide of type III collagen (PIIINP) was shown to be
up-regulated in SSc patients compared to healthy patients and proposed as a diagnostic and
treatment efficacy biomarker [19, 20, 22, 32]. However, the PIIINP assay detects both degrada-
tion and formation. The pro-peptide is not always cleaved of, thereby attached to the molecule
resulting in thin fibrils with abnormally cross-links and prone to rapid metabolic turnover[33,
34]. This warrants investigation of PRO-C3 in SSc as it is a true formation biomarker detecting
the amino acid sequence exposed, when the pro-peptide is cleaved of. In the current study, we
found that PRO-C3 was increased in SSc compared to asymptomatic controls, but only in the
early diffuse SSc patients. PRO-C3 was furthermore the best diagnostic biomarker between
early and late diffuse SSc. With these results, PRO-C3 appears to be a better biomarker of type
III collagen formation in SSc.
Type VI collagen is suggested to play a large role in the assembly of the collagenous matrix
in the dermis[35]. Our study underlines the importance of type VI collagen in SSc as biomark-
ers of formation and degradation of type VI collagen was the most efficient biomarkers to dif-
ferentiate the three groups assessed. In addition, the diagnostic assessment of PRO-C6 gave an
AUC of 0.99 (sensitivity/specificity of 95%/95%), when assessing early diffuse SSc and asymp-
tomatic controls. This correlates with the increased expression of type VI collagen genes have
been observed in SSc patients[36]. Further analysis is needed to confirm these results, but bio-
markers of type VI collagen appears as promising diagnostic biomarkers for SSc.
Conclusion
In this study, protein fingerprint formation biomarkers of ECM turnover were shown to be
significantly different between asymptomatic controls and SSc (early, late or early+late). Type
VI collagen biomarkers (C6M and PRO-C6) showed to have high diagnostic power together
with several other biomarkers. This study indicates that serological assessment of ECM
Collagen turnover biomarkers as diagnostic toll in systemic sclerosis
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turnover is of great interest in SSc, both for investigation of disease pathogenesis, but also as
diagnostic tools.
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